Core Insights - UTime Limited has initiated comprehensive financial and legal due diligence on Bowen Therapeutics Inc, aiming to acquire the company to enhance its position in the innovative medical products sector [1][2][3] Company Overview - UTime Limited, established in 2008, focuses on providing cost-effective mobile devices globally and has recently shifted its commitment towards health and wellness through innovative medical wearable technologies since 2024 [5] Acquisition Strategy - The acquisition of Bowen Therapeutics is a strategic move for UTime, leveraging Bowen's strong reputation and unique R&D capabilities, particularly in the development of a monkeypox vaccine, to facilitate technological innovation and market expansion [2][3] Due Diligence Process - The due diligence process will encompass a thorough examination of Bowen Therapeutics's financial statements, assets, liabilities, cash flow, tax records, accounting systems, corporate governance, contracts, intellectual property rights, and any pending litigation [3][4] - This process is essential for UTime to assess potential risks and opportunities, ensuring informed decision-making aligned with the company's long-term growth strategy [4]
UTime Initiates Financial and Legal Due Diligence on Bowen Therapeutics